These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11844866)

  • 41. Advances in the development of next-generation anthrax vaccines.
    Friedlander AM; Little SF
    Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anthrax: clinical features, pathogenesis, and potential biological warfare threat.
    Friedlander AM
    Curr Clin Top Infect Dis; 2000; 20():335-49. PubMed ID: 10943532
    [No Abstract]   [Full Text] [Related]  

  • 43. Anthrax Toxins in Context of Bacillus anthracis Spores and Spore Germination.
    Cote CK; Welkos SL
    Toxins (Basel); 2015 Aug; 7(8):3167-78. PubMed ID: 26287244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anthrax toxins].
    Brossier F; Guidi-Rontani C; Mock M
    C R Seances Soc Biol Fil; 1998; 192(3):437-44. PubMed ID: 9759382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
    Loving CL; Khurana T; Osorio M; Lee GM; Kelly VK; Stibitz S; Merkel TJ
    Infect Immun; 2009 Jan; 77(1):255-65. PubMed ID: 18955474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New clue to how anthrax kills.
    Strauss E
    Science; 1998 May; 280(5364):676. PubMed ID: 9599144
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys.
    Chawla A; Midha S; Bhatnagar R
    Biotechnol J; 2009 Mar; 4(3):391-9. PubMed ID: 19296443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dr. Jekyll and Mr. Hyde: a short history of anthrax.
    Schwartz M
    Mol Aspects Med; 2009 Dec; 30(6):347-55. PubMed ID: 19577591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bacillus anthracis genomic DNA enhances lethal toxin-induced cytotoxicity through TNF-α production.
    Jeon JH; Kim YH; Choi MK; Kim KA; Lee HR; Jang J; Kim YR; Chun JH; Eo SK; Kim TS; Rhie GE
    BMC Microbiol; 2014 Dec; 14():300. PubMed ID: 25472474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular basis for improved anthrax vaccines.
    Brey RN
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1266-92. PubMed ID: 15935874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
    Stokes MG; Titball RW; Neeson BN; Galen JE; Walker NJ; Stagg AJ; Jenner DC; Thwaite JE; Nataro JP; Baillie LW; Atkins HS
    Infect Immun; 2007 Apr; 75(4):1827-34. PubMed ID: 17145938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
    Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
    Bouzianas DG
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
    Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
    Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
    Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.
    Mangal S; Pawar D; Agrawal U; Jain AK; Vyas SP
    Artif Cells Nanomed Biotechnol; 2014 Feb; 42(1):47-57. PubMed ID: 23452384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.
    Brossier F; Lévy M; Landier A; Lafaye P; Mock M
    Infect Immun; 2004 Nov; 72(11):6313-7. PubMed ID: 15501759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anthrax revisited: Bacillus anthracis toxins as novel actors of immune escape?].
    Tournier JN; Quesnel-Hellmann A; Cleret A; Mathieu J; Goossens PL; Mock M; Vidal DR
    Bull Acad Natl Med; 2006 Jan; 190(1):155-63; discussion 163-7. PubMed ID: 16878452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
    Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
    Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.